Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
- Bronstein, Gewirtz & Grossman, LLCBronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmBronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Aardvark securities: (1) pursuant to...
- AIVITA Biomedical Strengthens Board of Directors with Appointment of Global Health and Vaccine Readiness Leader Larry BrilliantIRVINE, Calif., August 18, 2026--AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer, today announced the appointment of renowned physician, epidemiologist, technologist, philanthropist, and author Larry Brilliant, M.D., M.P.H., to its board of directors. Dr. Brilliant brings globally recognized expertise in epidemiology, pandemic preparedness, and vaccine readiness that is especially relevant to AIVIT
- Consano BioConsano Bio Receives FDA Fast Track Designation for C-1101 in Chronic, Painful Lumbosacral Radiculopathy (LSR) or Chronic SciaticaDesignation follows recent FDA clearance of the Company's IND application for C-1101, an investigational, potentially disease-modifying non-opioid biologic — Consano Bio, Inc., a clinical-stage biotechnology company advancing novel...
- PharmaTher Holdings Ltd.PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)Marks the first milestone in PharmaTher's three-stage commercialization plan, advancing PERSONALIZ3D™ into early commercialization activitiesEstablishes the operating foundation to scale telehealth-enabled personalized medicines and pharmaceutical 3D printing, with the potential to generate recurring revenue across multiple channelsToronto, Ontario--(August 18, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a life sciences company...
- Stuart Therapeutics, Inc.Stuart Therapeutics, Inc. Appoints David Jakeman as Chief Financial OfficerSTUART, Fla., August 18, 2026--Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of David Jakeman as chief financial officer. Jakeman will lead the company's finance and accounting operations as Stuart advances its lead candidate, ST-100 for dry eye disease, through completion of its pending Phase 3b clinical trial and into preparations for commercializ
- Harbour BioMedHarbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid TumorsHarbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas,...
- OncoOne Establishes Scientific Advisory Board to Support its Modular PreTarg-it® Platform for Radionuclide TherapiesVIENNA, August 18, 2026--OncoOne, a biotechnology company utilizing its expert knowledge in antibody engineering to support the further growth of targeted radiopharmaceutical therapies globally, announced their new Scientific Advisory Board (SAB) members whose collective expertise spans foundational research, translational medicine and scientific collaborations. The interdisciplinary guidance from the SAB will be instrumental in advancing and broadening the company’s PreTarg-it®, a modular platf
- Dunbar PharmaceuticalsDunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS PharmaATHLONE, Ireland, August 18, 2026--Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma
- LEO PharmaLEO Pharma Further Strengthens Late-Stage Pipeline With the Acquisition of DersimelagonBALLERUP, Denmark, August 18, 2026--LEO Pharma, a global leader in medical dermatology delivering innovative solutions for skin disease, today announces that it has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma. Dersimelagon is an oral, once-daily small MC1R agonist being developed for EPP and XLP.
- Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in AustraliaHansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication...
- Ingenia Therapeutics Goes Public on KOSDAQ to Accelerate Pipeline of Next-Generation Vascular Antibody TherapeuticsWATERTOWN, Mass., August 18, 2026--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced today that its shares have begun trading on the KOSDAQ market. The IPO marks a significant milestone as the company accelerates the development and global commercialization of its proprietary vascular stabilization pipeline.